Local clinical trial approval times in the UK

被引:0
|
作者
Chester P. [1 ,4 ]
Aalam S. [2 ]
Cooper P. [2 ]
Risley C. [2 ]
Dornhorst A. [3 ]
机构
[1] Oxford Centre for Diabetes Endocrinology and Metabolism, Churchill Hospital, Oxford
[2] Kendle UK Ltd., Crowthorne
[3] Hammersmith Hospital, London
[4] Oxford Centre for Diabetes Endocrinology and Metabolism, Churchill Hospital, Oxford
关键词
National Health Service; Insulin Detemir; Primary Care Trust; Investigational Medicinal Product; National Health Service Hospital;
D O I
10.2165/00124363-200620050-00006
中图分类号
学科分类号
摘要
Aim: This study aimed to evaluate the impact of local approval times on the schedule of a large multicentre study in the UK. Method: We reviewed the approval times of 178 applications that were made to the UK National Health Services Trusts (across 159 hospitals and 19 primary care trusts). Results: The mean time for approval was 82 days; more than half the submissions (94; 53%) took longer than 60 days for a decision. The reason for taking over 60 days varied but review of the trial documentation revealed that delays occurred in the Hospital R&D Office for 25 (14%) submissions, at the hospital or primary care trust level for 14 (8%) submissions, while the investigator was responsible for 23 (13%) applications taking longer than 60 days. Conclusion: Local submissions are a source of delayed start up in many centres participating in clinical trials; however, reasons for delay are not consistent across the applications and cannot be attributed to one specific part of the local approval process. © 2006 Adis Data Information BV. All rights reserved.
引用
收藏
页码:317 / 320
页数:3
相关论文
共 50 条
  • [1] Applying for regulatory approval of a clinical trial of a medical device in the UK - A practical guide
    Ria, S.
    Bakir, A.
    Abeysiri, S.
    Bister, D.
    Set, P.
    Navaie, W.
    Abela, S.
    [J]. BRITISH DENTAL JOURNAL, 2018, 225 (11) : 1033 - 1036
  • [2] UK Regulatory Approval Granted for Stroke Stem Cell Therapy Clinical Trial
    不详
    [J]. ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 2009, 37 (01): : 7 - 8
  • [3] Applying for regulatory approval of a clinical trial of a medical device in the UK – A practical guide
    S. Ria
    A. Bakir
    S. Abeysiri
    D. Bister
    P. Set
    W. Navaie
    S. Abela
    [J]. British Dental Journal, 2018, 225 : 1033 - 1036
  • [4] New drug approval times and clinical evidence in Japan
    Ono, S
    Yoshioka, C
    Asaka, O
    Tamura, K
    Shibata, T
    Saito, K
    [J]. CONTEMPORARY CLINICAL TRIALS, 2005, 26 (06) : 660 - 672
  • [5] Approval times for a multi-centre diabetes study in UK primary care
    Chester, P.
    Khunti, K.
    [J]. DIABETIC MEDICINE, 2012, 29 (04) : 554 - 555
  • [6] Drug approval times
    Lexchin, J
    Mintzes, B
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2000, 162 (13) : 1803 - 1804
  • [7] UK APPROVAL FOR MIFEPRISTONE
    不详
    [J]. LANCET, 1991, 338 (8759): : 111 - 112
  • [8] The changing landscape of clinical trial and approval processes in China
    Qing Zhou
    Xiao-Yuan Chen
    Zhi-Min Yang
    Yi-Long Wu
    [J]. Nature Reviews Clinical Oncology, 2017, 14 : 577 - 583
  • [9] India issues new requirements for clinical trial approval
    Bagcchi, Sanjeet
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
  • [10] Ethicists bemoan shortened clinical trial approval time
    Dove, A
    [J]. NATURE MEDICINE, 1999, 5 (12) : 1336 - 1336